GT Biopharma GTBP Institutional Ownership

Updated Oct 10, 2026

GT Biopharma, Inc. (NASDAQ:GTBP) counted 56 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• Collectively, these holders controlled 4.74% of GT Biopharma's outstanding shares in Q2 2026, up from 4.59% in Q1 2026.
• Total holdings of GT Biopharma shares rose 31.24% from Q1 2026, and the number of holders rose 300.00% from Q2 2025.
• Of the 56 holders, 32 added to their positions, 6 reduced their stakes and 18 left their positions unchanged in Q2 2026.
• In total, institutional investors held 84.69K shares of GT Biopharma at the end of Q2 2026, up 20.16K from the prior quarter and up 76.9K from a year earlier.
• Vanguard Capital Management LLC held the largest position in GTBP at 15.06K shares as of June 30, 2026, or 0.84% of shares outstanding.
• The biggest increases in GTBP positions during Q2 2026 came from Integrated Wealth Concepts LLC (+800 shares), Osaic Holdings, Inc. (+700 shares), StoneX Group Inc. (+340 shares), Royal Bank of Canada (+299 shares) and LPL Financial LLC (+240 shares).
• On the other side, among holders that kept a position in GT Biopharma, the largest reductions in Q2 2026 came from Vanguard Capital Management LLC (-3.02K shares), Geode Capital Management, LLC (-1.11K shares), Two Sigma Securities, LLC (-736 shares), BlackRock, Inc. (-4 shares) and Wells Fargo & Company (-2 shares).
• GT Biopharma's 10 largest institutional shareholders as of Q2 2026 were Vanguard Capital Management LLC (15.06K shares), Geode Capital Management, LLC (10.67K shares), Vanguard Fiduciary Trust Co (9.04K shares), HRT Financial LP (4.29K shares), Everhart Financial Group, Inc. (4K shares), Arax Advisory Partners (3.75K shares), Opal Wealth Advisors, LLC (3.27K shares), Northern Trust Corp (3.02K shares), 49 Wealth Management, LLC (2.56K shares) and Alongside, LLC (2.56K shares), per Business Quant data.